Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum
We report a patient with GD type 1 who was diagnosed with corticobasal syndrome (CBS), a clinical atypical parkinsonism diagnosis, in his sixth decade of life. Our case highlights the need to consider forms of atypical parkinsonism such as CBS in addition to PD in the differential diagnosis of cognitive and motor changes in patients with GD type 1. We also recommend careful assessment and routine monitoring of cognition, mood, behavior, sleep patterns, olfaction, and memory in patients with GD type 1 to identify early symptoms indicative of neurological involvement.
January saw the union launch a campaign to encourage local government pension funds to divest from carbon – in other words, to pull their hard-earned money out of environment-unfriendly businesses. Some £16bn of local government pension funds is invested in fossil fuels and, with five million members in those schemes, the campaign can make an impact. Later that month, the higher education service group conference met in Chester. “We have to stand up for our members’ rights,” delegates agreed – particularly in the face of Brexit. Just over 10% of all university workers come from elsewher...
Katharina Maria Lex, Philip Larkin, J ürgen Osterbrink, Stefan Lorenzl
Benton S. Purnell, Roland D. Thijs, Gordon F. Buchanan
Paul F. Smith
Breast cancer survivors may be more likely to experience anxiety, depression, sleep troubles and other mental health issues than women who have not been diagnosed with the disease, a research review suggests.Reuters Health Information
(MedPage Today) -- " Under-recognized " risk factor in African-Americans
Two teams of scientists independently discovered that inhibiting an enzyme called stearoyl-CoA desaturase reduces the toxicity of α-synuclein, a protein implicated in Parkinson’s disease
This article is protected by copyright. All rights reserved. PMID: 29920646 [PubMed - as supplied by publisher]
To the Editor In a study published in JAMA Neurology, Beavan et al reported a 2-year follow-up study of 30 patients with a diagnosis of type 1 Gaucher disease, 28 heterozygous glucocerebrosidase gene (GBA) mutation carriers, and 26 control individuals. It is well known that GBA mutations are a confirmed genetic risk for developing Parkinson disease (PD). Previously, Winder-Rhodes et al found that GBA mutations were present at a frequency of 3.5% in a UK PD population, confirming the important contribution of this gene in the clinical progression of PD. Indeed, the authors found that the hazard ratio for progression both to...
Conclusions: Continued longitudinal evaluation of patients with Gaucher disease and heterozygous carriers of GBA1 mutations may help identify a pre-motor phase in this cohort at risk of developing parkinsonism. This pre-motor profile may suggest specific neurotransmitters involved in neurodegeneration and contribute to a better understanding of the association between lysosomal dysfunction and alpha-synuclein aggregation.Disclosure: Dr. Kim has nothing to disclose. Dr. Cintron has nothing to disclose. Dr. Wiggs has nothing to disclose. Dr. Groden has nothing to disclose. Dr. Sidransky has nothing to disclose. Dr. Lopez has...